FSFei Su

Fei Su

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fei Su has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gypenosides Mitigate STEC-Induced Intestinal Injury Through Modulation of Ferroptosis Involving the ATF4-CHAC1-GPX4 Axis

    by Fei Su, Liwen Liang, Bin Yu, Lihua Xu, Hongchao Sun, Shiyi Ye, Xiufang Yuan, Yin Xue, Canying Liu, Junxing Li

    Shiga toxin-producing Escherichia coli (STEC) infection causes severe enteropathies and hemolytic uremic syndrome, yet non-antibiotic therapeutic strategies remain limited. This study evaluated whether gypenosides (GPs) protect against STEC-induced intestinal injury and investigated the underlying mechanisms. Mice were pretreated with GPs prior to STEC challenge, and protective effects were comprehensively assessed through survival analysis, bacterial burden quantification, transcriptomic profiling, flow cytometry, electron microscopy, and Western blotting. GPs significantly improved survival rates, alleviated diarrheal symptoms, reduced bacterial dissemination in systemic organs, and lowered Stx2 toxin levels. Furthermore, GPs effectively restored gut microbiota dysbiosis by enriching beneficial bacterial genera. Transcriptomic analysis suggested that GP treatment was associated with suppression of ferroptosis-related signaling pathways. Ultrastructural examination demonstrated ameliorated mitochondrial vacuolization, and biochemical assays confirmed decreased Fe2+ accumulation and attenuated lipid peroxidation. Mechanistically, these changes were associated with modulation of the ATF4-CHAC1-GPX4 axis and suppression of ferroptosis, together with preservation of mitochondrial integrity. Collectively, these findings identify GPs as a promising protective candidate against STEC-induced intestinal injury and highlight the ATF4-CHAC1-GPX4 axis as a candidate pathway for further mechanistic investigation.

  • Open Access

    Isolation and Molecular Characterization of Emerging Getah Virus Genotype III Variant Strains from Swine in Southeastern China (2024–2025)

    by Xiufang Yuan, Bin Yu, Xingyuan Ma, Lihua Xu, Fei Su, Hongchao Sun, Kang Shao, Tao Xiong, Junxing Li, Shiyi Ye

    As a member of the Alphavirus genus, Getah virus (GETV) has become an emerging pathogen posing severe threats to animal health and public health security. In recent years, GETV has caused increasing outbreaks in swine herds, leading to substantial economic losses in the pig industry in China. Here, we report continuous GETV outbreaks on pig farms across southeastern China between September 2024 and December 2025. A total of 185 clinical samples were examined, among which 27 were positive (14.6%). Subsequently, five GETV strains were successfully isolated and subjected to whole-genome sequencing. Phylogenetic analysis revealed that all the 5 isolated strains belonged to genotype III(GIII), with two strains (GETV-AHX2024 and GETV-JS2024) forming a distinct GIII variant clade. Notably, multiple specific amino acid mutations were identified in the nsp3, C, E2, 6K, and E1 proteins and 3′UTR of these GIII variant strains. Pathogenicity in mice revealed that mice infected with the GIII variant strain GETV-JS2024 exhibited a longer viral shedding period compared with other strains. These findings highlight the emergence of GETV GIII variant strains in southeastern China and suggest their altered pathogenic performance in mice. These results supplied critical data for molecular surveillance and subsequent pathogenic analysis of GETV in China.


  • Open Access

    Early Oral Administration of Ginseng Stem-Leaf Saponins Enhances the Peyer’s Patch-Dependent Maternal IgA Antibody Response to a PEDV Inactivated Vaccine in Mice, with Gut Microbiota Involvement

    by Fei Su, Junxing Li, Yin Xue, Bin Yu, Shiyi Ye, Lihua Xu, Yuan Fu, Xiufang Yuan

    Neonatal piglets during the first week of life are highly susceptible to porcine epidemic diarrhoea virus (PEDV) infection, with mortality rates reaching 80–100%. Passive lactogenic immunity remains the most effective way to protect neonates from infection. Although safe, inactivated vaccines provide little or no passive protection. Here, we administered ginseng stem-leaf saponins (GSLS) to mice before parenteral immunization with an inactivated PEDV vaccine to investigate the effect of GSLS on the gut–mammary gland (MG)–secretory IgA axis. Early oral GSLS administration potently increased PEDV-specific IgA plasma cell generation in the intestine, facilitated intestinal IgA plasma cell migration to the MG by enhancing the chemokine receptor (CCR)10-chemokine ligand (CCL)28 interaction, and ultimately promoted specific IgA secretion into milk, which was dependent on Peyer’s patches (PPs). Additionally, GSLS improved the gut microbiota composition, especially increasing probiotic abundance, and these microflora members promoted the GSLS-enhanced gut–MG–secretory IgA axis response and were regulated by PPs. In summary, our findings highlight the potential of GSLS as an oral adjuvant for PEDV-inactivated vaccines and provide an attractive vaccination strategy for lactogenic immunity induction in sows. Further studies are required to evaluate the mucosal immune enhancement efficacy of GSLS in pigs.


  • Open Access

    Immune Enhancement of Nanoparticle-Encapsulated Ginseng Stem-Leaf Saponins on Porcine Epidemic Diarrhea Virus Vaccine in Mice

    by Fei Su, Lihua Xu, Yin Xue, Wei Xu, Junxing Li, Bin Yu, Shiyi Ye, Xiufang Yuan

    Porcine epidemic diarrhea virus (PEDV) causes severe enteric disease in pigs, particularly neonatal piglets. Current vaccines do not provide complete protection against PEDV. Ginseng stem-leaf saponins (GSLS), a promising oral adjuvant candidate, can improve intestinal immune responses in poultry and mice. However, its low stability limits further use. Poly lactic-co-glycolic acid (PLGA), a biocompatible and biodegradable nanoparticle, has been widely used in biomedicine for stable and targeted drug delivery. In this study, we developed GSLS-PLGA nanoparticles (GSLS-NPs) and evaluated the mucosal adjuvant efficacy in vitro and in vivo. GSLS-NPs significantly enhanced antigen internalization and pro-inflammatory cytokine secretion by DC2.4 cells. Mice orally administered GSLS-NPs before intramuscular inoculation generated CD11b+CD8α− and CD11b−CD103+ dendritic cells in the spleen and draining mesenteric lymph nodes, respectively, which are the types mainly responsible for antigen presentation. Additionally, enhanced neutralizing and non-neutralizing antibody responses and expanded activities of specific effector and memory CD4+ and CD8+ T cells were also observed in mice immunized with PEDV vaccines plus GSLS-NPs compared to mice receiving the vaccines alone. Furthermore, GSLS-NPs showed a good safety profile and presented great advantages over GSLS aqueous solution. Collectively, our results highlight the potential of GSLS-NPs as a mucosal adjuvant and provide an attractive vaccination strategy for combatting PEDV. Further study is required to evaluate the efficacy of this mucosal adjuvant in swine.


  • Open Access

    Immune Enhancement of Nanoparticle-Encapsulated Ginseng Stem-Leaf Saponins on Porcine Epidemic Diarrhea Virus Vaccine

    by Fei Su, Lihua Xu, Yin Xue, Wei Xu, Junxing Li, Bin Yu, Shiyi Ye, Xiufang Yuan

    Porcine epidemic diarrhea virus (PEDV) causes severe enteric disease in pigs, particularly neonatal piglets. Attempts to develop a safe and effective vaccine have been unsuccessful. Ginseng stem-leaf saponins (GSLS), a promising oral adjuvant candidate, can improve intestinal immune responses in poultry and mice. However, the low stability limits the further use. Poly lactic-co-glycolic acid (PLGA), a biocompatible and biodegradable nanoparticle, have been widely used in biomedicine for stable and targeted drug delivery. In this study, we developed GSLS-PLGA nanoparticles (GSLS-NPs) and evaluated the mucosal adjuvant efficacy in vitro and in vivo. GSLS-NPs significantly enhanced antigen internalization and pro-inflammatory cytokine secretion by DC2.4 cells. Mice orally administered GSLS-NPs before intramuscular inoculation generated CD11b+CD8α- and CD11b-CD103+ dendritic cells in the spleen and draining mesenteric lymph nodes, respectively, which are the types mainly responsible for antigen presentation. Additionally, enhanced neutralizing and non-neutralizing antibody responses and expanded activities of specific effector and memory CD4+ and CD8+ T cells were also observed in mice immunized with PEDV vaccines plus GSLS-NPs compared to mice receiving the vaccines alone. Furthermore, GSLS-NPs showed a good safety profile and presented great advantages over GSLS aqueous solution. Collectively, our results highlight the potential of GSLS-NPs as a mucosal adjuvant and provide an attractive vaccination strategy for combatting PEDV. Further study is required to evaluate the efficacy of this mucosal adjuvant in swine.


  • Open Access

    Escherichia coli Heat-Labile Enterotoxin B Subunit Combined with Ginsenoside Rg1 as an Intranasal Adjuvant Triggers Type I Interferon Signaling Pathway and Enhances Adaptive Immune Responses to an Inactivated PRRSV Vaccine in ICR Mice

    by Fei Su, Yige Wu, Junxing Li, Yee Huang, Bin Yu, Lihua Xu, Yin Xue, Chenwen Xiao, Xiufang Yuan

    Porcine reproductive and respiratory syndrome virus (PRRSV) is a major pathogen that has threatened the global swine industry for almost 30 years. Because current vaccines do not provide complete protection, exploration of new preventive strategies is urgently needed. Here, we combined a heat-labile enterotoxin B subunit of Escherichia coli (LTB) and ginsenoside Rg1 to form an intranasal adjuvant and evaluated its enhancement of immune responses in mice when added to an inactivated-PRRSV vaccine. The combination adjuvant synergistically elicited higher neutralizing and non-neutralizing (immunoglobulin G and A) antibody responses in the circulatory system and respiratory tract, and enhanced T and B lymphocyte proliferation, CD4+ T-cell priming, and cytotoxic CD4+ T cell activities in mononuclear cells from spleen and lung tissues when compared to the PRRSV vaccine alone, and it resulted in balanced Th1/Th2/Th17 responses. More importantly, we observed that the combination adjuvant also up-regulated type I interferon signaling, which may contribute to improvement in adaptive immune responses. These results highlight the potential value of a combined adjuvant approach for improving the efficacy of vaccination against PRRSV. Further study is required to evaluate the efficacy of this combined adjuvant in swine.